Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI (SWAP-AC-2)
Coronary Artery Disease
About this trial
This is an interventional treatment trial for Coronary Artery Disease focused on measuring percutaneous coronary intervention, dual antiplatelet therapy, oral anticoagulant
Eligibility Criteria
Inclusion criteria:
- Age ≥ 18 years
- Willing and able to provide written informed consent
- Undergone successful PCI and treated with DAPT (aspirin plus a P2Y12 inhibitor) per standard of care
- On treatment with a novel oral anticoagulant (apixaban, dabigatran, edoxaban, or rivaroxaban) for any indication (dosing regimen will be according to standard of care and at the discretion of the treating physician)
Exclusion criteria:
- Any active bleeding or history of major bleeding
- Ischemic Stroke within 1 month
- Any history of hemorrhagic stroke, or intracranial hemorrhage
- Known non-cardiovascular disease that is associated with poor prognosis (e.g., metastatic cancer) or that increases the risk of an adverse reaction to study interventions.
- End-stage renal disease on hemodialysis
- Known severe liver dysfunction or any known hepatic disease associated with coagulopathy
- History of hypersensitivity or known contraindication to clopidogrel or ticagrelor.
- Systemic treatment with strong inhibitors of both CYP 3A4 and p-glycoprotein (e.g., systemic azole antimycotics, such as ketoconazole, and human immunodeficiency virus [HIV]-protease inhibitors, such as ritonavir), or strong inducers of CYP 3A4, i.e.
rifampicin, rifabutin, phenobarbital, phenytoin, and carbamazepine
- Subjects who are pregnant, breastfeeding, or are of childbearing potential, and sexually active and not practicing an effective method of birth control (e.g. surgically sterile, prescription oral contraceptives, contraceptive injections, intrauterine device, double barrier method, contraceptive patch, male partner sterilization)
- Concomitant participation in another study with investigational drug
- Hemoglobin ≤9 mg/dL
- Platelet count <80x106/mL
Sites / Locations
- University of FloridaRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Experimental
Active Comparator
ABCD-GENE >10 - Clopidogrel
ABCD-GENE >10 - Ticagrelor
ABCD-GENE <10 - Clopidogrel
Patients with an ABCD-GENE>10 score will be randomized in a 1:1 fashion to ticagrelor (60 mg/bid) or clopidogrel (75 mg/qd). Treatment will be maintained for 30 days.
Patients with an ABCD-GENE>10 score will be randomized in a 1:1 fashion to ticagrelor (60 mg/bid) or clopidogrel (75 mg/qd). Treatment will be maintained for 30 days.
Patients with an ABCD-GENE<10 will be treated with clopidogrel (75 mg/qd) for 30 days.